7,376.86

+23.13

+0.31%

51,285.73

-237.33

-0.46%

24,579.42

+264.43

+1.09%

2,754.11

+24.22

+0.89%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,074.90

-38.60

-0.94%

75,956.85

+475.85

+0.63%

Crude Oil Dec 26

90.83

+0.31

+0.34%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Delayed Quote USD

Dyadic International, Inc. (DYAI)

0.3398 -0.0003 (-0.09%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for DYAI

Chart Range Bar

Interval:

In partnership with ChartIQ

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026

DYAI: Second Quarter Results

DYAI: Second Quarter Results

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement

Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ...

Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ...

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Dyadic Expands IP Protection and Business Development Activities in Japan

Dyadic Expands IP Protection and Business Development Activities in Japan

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Mobilize your Website

View Site in Mobile | Classic

Share by: